Passage Bio Inc

Research Passage Bio Inc (PASG) on Bullrun: market cap USD 15.56M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPASG
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 15.56M
• Financial periodFY2025
• Net income-USD 46.00M

Valuation Snapshot

latest market cap is USD 15.56M.

About Passage Bio Inc

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis;

Frequently asked questions

What is Passage Bio Inc's market cap?

Passage Bio Inc's market capitalization is USD 15.56M.

What does Passage Bio Inc do?

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency;